All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications ... in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk ...

and other hematological malignancy research will be presented at the conferenceThree of the 13 posters were selected to be presented in two sessions dedicated to “Acute Myeloid Leukemias (AML ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

increasing the potential of cancer relapse. Dr. Orvain and his colleagues analyzed data from 1,265 adult patients with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS)/AML who underwent ...

As a significant step in spreading awareness, the association unveiled a cancer awareness poster, which highlights early warning signs and preventive measures. This poster will be displayed in all ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...